MedPath

Ultrasound-Guided Percutaneous Neuromodulation on the Superior Gluteal Nerve in Patients With Greater Trochanteric Pain Syndrome: A Pilot Study

Not Applicable
Not yet recruiting
Conditions
Greater Trochanteric Pain Syndrome
Interventions
Other: Shockwave Therapy
Other: Therapeutic Exercises
Registration Number
NCT06529783
Lead Sponsor
Universidad de Zaragoza
Brief Summary

Greater Trochanteric Pain Syndrome (GTPS) predominantly affects women, with an annual incidence of 1.8 to 5.6 per 1000 individuals and a prevalence ratio of 4:1 compared to men. It is characterized by lateral pain in the greater trochanter region, particularly during palpation, prolonged sitting, and physical activity. Conservative treatments, such as radial shockwave therapy and therapeutic exercises, are effective but slow, and some patients eventually require surgery.

Ultrasound-guided percutaneous neuromodulation, targeting the superior gluteal nerve, has emerged as a promising alternative to improve GTPS outcomes. This technique aims to normalize motor response and reduce pain more rapidly than conventional therapies. Integrating neuromodulation could accelerate recovery, enhancing both pain relief and tendon functionality. This study aims to explore the effectiveness of this technique as an adjunct to conventional treatments, aiming for faster symptom improvement and better long-term adherence.

Detailed Description

Greater Trochanteric Pain Syndrome (GTPS) is a condition primarily affecting women, with an annual incidence ranging from 1.8 to 5.6 per 1000 individuals and a prevalence ratio of 4:1 compared to men. Formerly known as trochanteric bursitis, this syndrome is characterized by lateral pain in the region of the greater trochanter, particularly manifesting during palpation, prolonged sitting, and physical activity. The primary cause of GTPS is attributed to repetitive friction between the greater trochanter and the iliotibial band, resulting in gluteus medius or minimus tendinopathy, as well as other associated conditions such as trochanteric bursitis and iliotibial band syndrome.

Conservative treatment is the first-line approach for GTPS, with radial shockwave therapy and therapeutic exercises demonstrating long-term efficacy. However, a percentage of patients require surgical intervention due to a lack of response to conservative treatments.

Ultrasound-guided percutaneous neuromodulation, a technique utilizing electrical stimulation via a needle guided by ultrasound, has emerged as a potential alternative to improve therapeutic outcomes for GTPS. In this study, this technique targets the superior gluteal nerve, which innervates the gluteus medius, minimus, and tensor fasciae latae, with the aim of normalizing motor response and reducing pain. Neuromodulation could provide a faster improvement in symptoms and motor patterns compared to conventional therapies, which require prolonged periods to be effective.

Given that current treatments for GTPS, such as shockwave therapy and therapeutic exercises, are effective but slow in progress, the integration of percutaneous neuromodulation could accelerate patient recovery, improving both pain relief and mechanical functionality of the tendon. This combined approach has the potential not only to optimize clinical outcomes but also to reduce the need for surgical interventions in GTPS patients.

In summary, this study proposes to explore the effectiveness of superior gluteal nerve neuromodulation as an adjunct to conventional treatments for GTPS. The research aims to demonstrate whether this technique can significantly expedite pain reduction and motor pattern improvement, thereby enhancing long-term treatment adherence and tolerance.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Suffering from Greater Trochanteric Pain Syndrome (GTPS).
  • Experiencing local pain upon palpation of the greater trochanter area.
  • Having pain in the greater trochanter region lasting more than three months, indicating chronicity.
  • Being over 18 years of age.
  • Experiencing pain when bearing weight on the affected trochanter.
  • Having pain that impairs the functionality of resisted hip abduction.
Exclusion Criteria
  • Radiological evidence of pathology in the hip or knee joints.
  • Blood coagulation disorders.
  • Use of oral anticoagulants.
  • Presence of infections.
  • History of disc or hip surgery.
  • Presence of dysplasia, deformities, or sciatica.
  • History of vascular, neurological, or neoplastic diseases.
  • Specific contraindications for ultrasound-guided percutaneous neuromodulation (UG-PNM): belenophobia, pregnancy, pacemakers, epilepsy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Shockwave Therapy + Therapeutic ExercisesTherapeutic ExercisesPatients on this group receive two interventions based on Shockwave Therapy and Therapeutic Exercises
Shockwave Therapy + Therapeutic Exercises + US-Guided percutaneous neuromodulationShockwave TherapyPatients on this group receive both interventions previously described and ultrasound-guided percuteneous neuromodulation is added.
Shockwave Therapy + Therapeutic ExercisesShockwave TherapyPatients on this group receive two interventions based on Shockwave Therapy and Therapeutic Exercises
Shockwave Therapy + Therapeutic Exercises + US-Guided percutaneous neuromodulationTherapeutic ExercisesPatients on this group receive both interventions previously described and ultrasound-guided percuteneous neuromodulation is added.
Primary Outcome Measures
NameTimeMethod
Functional capacityThis variable is measured five times, corresponding with the five participant visits (day 1, week 4, week 8, week 16, and year 1).

Functionality will be assessed using the Visa-G questionnaire, which consists of 8 questions divided into three main aspects: pain, function, and activity. The first 7 questions score up to 10 points each, while question 8 has a maximum score of 30. An asymptomatic person would score a total of 100 points; thus, a lower score indicates greater disability severity.

Secondary Outcome Measures
NameTimeMethod
Pain on Palpation of the Greater Trochanterday 1, week 4, week 8, week 16, and year 1

Pain on palpation, performed by the physiotherapist, is also measured using the VAS

Adverse Effectsday 1, week 4, week 8, week 16, and year 1

Adverse effects for this study include pain during the treatment session, pain after the session, inflammation and/or redness in the treated area, bruising in the treated region, dizziness, muscle fatigue, numbness, and drowsiness. These are assessed through the participant's oral reports.

Adherence to the Therapeutic Exercise Protocolday 1, week 4, week 8, week 16, and year 1

Adherence is assessed by asking the patient in each session if they are following the protocol correctly, with an emphasis on honesty to ensure accurate recording of adherence.

Pain on the Day Prior to the VisitThis variable is collected on five occasions, coinciding with the five participant visits (day 1, week 4, week 8, week 16, and year 1)

Pain is measured using the Visual Analog Scale (VAS).

Hip Abductor Muscle Strengthday 1, week 4, week 8, week 16, and year 1

Strength is measured using an Active Force 2 dynamometer

Trial Locations

Locations (1)

University of Zaragoza

🇪🇸

Zaragoza, Spain

© Copyright 2025. All Rights Reserved by MedPath